Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Share News (CSRT)

  • There is currently no data for CSRT

EnCore founder reduces stake

Wed, 28th Oct 2009 16:09
EnCore Oil finance director Eugene Whyms raised £289,000 from the sale of 2m shares in the oil and gas explorer at 14.45p each. That leaves him with 7.4m shares. Whyms is a founder of EnCore, which reversed into AIM-quoted Oil Quest Resources in March 2006. At that point, Whyms owned just over 8.5m shares. The EnCore share price peaked at 58.5p in the first half of 2008. EnCore's exploration focus is the UK Continental Shelf but it also has onshore assets in France and one exploration licence offshore of Africa. EnCore is talking to AIM-quoted Egdon Resources about the sale of its onshore assets in France and the UK plus a stake in the Ceres gas field which commenced production this month. EnCore would receive Egdon shares in return for the assets but it would not take a stake that exceeded 29.9% of Egdon. Egdon specialises in onshore oil and gas assets. In August, EnCore sold its 15% stake in the Breagh gas discovery to RWE in return for $44.7m and the repayment of inter-company loans of £14.7m. One-fifth of this cash will be held in escrow for one year in order to cover any warranty claims. Including the cash in escrow, house broker Hanson Westhouse reckons that EnCore has cash of around £46m - almost equivalent to EnCore's market value. EnCore has approval to buy back up to 100m shares, which is nearly one-third of its share capital. That is equivalent to around £15m at the current share price. Earlier this month, EnCore bought back a total of 1.25m shares at 14.5p each.That still leaves plenty of cash to finance an appraisal well on the Cladhan discovery and an exploration well on the Catcher prospect. There are also plans for a gas storage project at Esmond in the North Sea. There is a shortage of gas storage capacity in the UK. Esmond produced gas between 1985 and 1995. EnCore wants to find a partner to help finance this development. The total capital expenditure on the project is estimated at £1.1bn, while operating expenses will be £15m a year. Even if everything goes to plan the storage project will not be completed until 2015. Top Director BuysCamper & Nicholsons Marina Investments Ltd. (CNMI) Director name: Mr Christopher LewintonAmount purchased: 150,000 @ 15.00p Value: £22,500Camper & Nicholsons Marina Investments Ltd. (CNMI) Director name: Mr Nicholas MarisAmount purchased: 150,000 @ 15.00p Value: £22,500Jetion Solar Holdings (JHL) Director name: Mr Eric ChanAmount purchased: 30,000 @ 65.00p Value: £19,500Northgate (NTG) Director name: Mr Bob (Robert) ContrerasAmount purchased: 6,001 @ 241.50p Value: £14,492Jetion Solar Holdings (JHL) Director name: Mr Eric ChanAmount purchased: 20,000 @ 62.50p Value: £12,500Top Director SellsEncore Oil (EO.) Director name: Mr Eugene WhymsAmount sold: 2,000,000 @ 14.50p Value: £290,000Consort Medical (CSRT) Director name: Mr Paul V BoughtonAmount sold: 20,363 @ 410.00p Value: £83,488

Related News

DIRECTOR DEALINGS SUMMARY: IWG And Man Chiefs Buy GBP3 Million Worth
17 Mar 2020

DIRECTOR DEALINGS SUMMARY: IWG And Man Chiefs Buy GBP3 Million Worth

DIRECTOR DEALINGS SUMMARY: IWG And Man Chiefs Buy GBP3 Million Worth

DIRECTOR DEALINGS SUMMARY: Ocado Chair Rose Sells GBP1.7 Million Worth
27 Feb 2020

DIRECTOR DEALINGS SUMMARY: Ocado Chair Rose Sells GBP1.7 Million Worth

DIRECTOR DEALINGS SUMMARY: Ocado Chair Rose Sells GBP1.7 Million Worth

Director dealings: Redde Northgate CEO makes share purchase
26 Feb 2020

Director dealings: Redde Northgate CEO makes share purchase

(Sharecast News) - Redde Northgate revealed on Wednesday that chief executive officer Martin Ward had purchased 76,537 ordinary shares in the London-l...

CSRT.L News

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition
17 Feb 2020

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition

Recipharm Holds 91% Consort Stake, To Implement Compulsory Acquisition

Monday broker round-up
10 Feb 2020

Monday broker round-up

(Sharecast News) - Consort Medical: RBC Capital Markets upgrades to sector performer with a target price of 1,010p.

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional
4 Feb 2020

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional

Recipharm Lowers Acceptance Condition; Consort Offer Now Unconditional

Recipharm To Make No Further Changes To Consort Medical Offer
29 Jan 2020

Recipharm To Make No Further Changes To Consort Medical Offer

Recipharm To Make No Further Changes To Consort Medical Offer

Recipharm Extends Consort Medical Offer Deadline To February 4
24 Jan 2020

Recipharm Extends Consort Medical Offer Deadline To February 4

Recipharm Extends Consort Medical Offer Deadline To February 4

Recipharm Buys 10% Of Takeover Target Consort Medical
22 Jan 2020

Recipharm Buys 10% Of Takeover Target Consort Medical

Recipharm Buys 10% Of Takeover Target Consort Medical

Recipharm's Consort Medical Takeover Clears German Regulatory Hurdle
14 Jan 2020

Recipharm's Consort Medical Takeover Clears German Regulatory Hurdle

Recipharm's Consort Medical Takeover Clears German Regulatory Hurdle

Friday broker round-up
10 Jan 2020

Friday broker round-up

(Sharecast News) - Polymetal International: Berenberg upgrades to buy with a target price of 1,480p.